```html

Quinapril‑Induced Cough

What is Quinapril‑Induced Cough?

Quinapril is an angiotensin‑converting enzyme (ACE) inhibitor prescribed for hypertension, heart failure, and diabetic nephropathy. One of the most frequent adverse effects of ACE inhibitors is a persistent, dry (non‑productive) cough. When the cough appears after starting quinapril—or after a dose increase—and improves when the medication is discontinued, it is referred to as “quinapril‑induced cough.” The mechanism is thought to involve accumulation of bradykinin and substance P in the respiratory tract, which irritates the airway lining and triggers the cough reflex.

Although the cough is usually harmless, it can be bothersome enough to affect sleep, daily activity, and medication adherence. Recognizing that quinapril is the cause is essential so that clinicians can adjust therapy without missing more serious lung conditions.

Common Causes

Quinapril‑induced cough is a diagnosis of exclusion; before attributing the symptom to quinapril, other conditions that can produce a similar dry cough should be considered. Below are 8–10 common causes that clinicians typically evaluate:

• Upper respiratory infections – viral or bacterial infections of the nose, throat, or sinuses.
• Asthma – hyper‑responsive airways that cause wheezing, shortness of breath, and cough.
• Chronic obstructive pulmonary disease (COPD) – especially chronic bronchitis.
• Gastro‑esophageal reflux disease (GERD) – acid reflux irritating the throat.
• Post‑nasal drip (rhinitis) – mucus drainage that triggers coughing.
• Bronchial hyper‑reactivity from environmental irritants – smoke, dust, chemicals.
• Other medication‑related coughs – e.g., β‑blockers, certain antihistamines, or aspirin‑exacerbated respiratory disease.
• Heart failure – pulmonary congestion may produce a cough that worsens when lying down.
• Interstitial lung disease – scarring of lung tissue causing dry cough.
• Tuberculosis or atypical mycobacterial infection – especially in immunocompromised patients.

Eliminating these possibilities helps confirm that quinapril itself is the likely trigger.

Associated Symptoms

While quinapril‑induced cough is typically dry and non‑productive, patients may notice other accompanying features:

• Tickling sensation or “scratchy throat.”
• Night‑time coughing that disrupts sleep.
• Hoarseness or a mild sore throat from repeated coughing.
• Occasional mild wheezing—usually due to airway irritation, not asthma.
• Absence of fever, chills, or purulent sputum (helps rule out infection).
• Improvement or resolution within 1–4 weeks after stopping quinapril.

When to See a Doctor

Most quinapril‑related coughs are not an emergency, but medical evaluation is warranted if any of the following appear:

• The cough persists for more than 2 weeks after starting or increasing quinapril.
• It interferes with sleep, work, or social activities.
• You develop fever, chills, shortness of breath, chest pain, or produce colored sputum.
• There is swelling of the lips, tongue, or face—possible sign of an allergic reaction.
• You have known lung disease (asthma, COPD) and notice a sudden worsening.
• Any concern about medication adherence or side‑effects.

Diagnosis

Diagnosis is based on clinical history, exclusion of other causes, and response to medication changes.

1. Detailed History

• Onset relative to quinapril initiation or dose change.
• Characteristics of the cough (dry vs. productive, timing, triggers).
• Review of other drugs, recent infections, allergies, and occupational exposures.

2. Physical Examination

• Listen to the lungs for wheezes, crackles, or signs of fluid.
• Examine the throat for erythema or post‑nasal drip.

3. Targeted Tests (to rule out other causes)

• Chest X‑ray – evaluates for pneumonia, heart failure, or interstitial disease.
• Spirometry – assesses for obstructive airway disease.
• Peak flow measurement if asthma is suspected.
• Upper endoscopy or pH monitoring if GERD is a strong possibility.
• Complete blood count (CBC) – looks for infection or eosinophilia.

4. Medication Challenge/Withdrawal

Most clinicians will discontinue quinapril (or switch to an angiotensin‑II receptor blocker, ARB) and observe symptom change for 2–4 weeks. Resolution strongly supports the diagnosis.

Treatment Options

Treatment focuses on eliminating the offending drug and managing symptoms while the body adjusts.

1. Discontinue or Substitute Quinapril

• Stop quinapril and start an ARB (e.g., losartan, valsartan) – ARBs have a comparable blood‑pressure effect without the bradykinin buildup.
• Switch to a different class of antihypertensive if ARBs are contraindicated (e.g., calcium‑channel blockers, thiazide diuretics).

2. Symptomatic Relief While Switching

• Honey or lozenges – coat the throat and reduce irritation.
• Humidifier – moist air lessens dry‑cough sensation.
• Over‑the‑counter cough suppressants containing dextromethorphan may be used short‑term.
• Inhaled bronchodilators (e.g., albuterol) if mild wheezing is present, after physician approval.

3. Address Contributing Conditions

• Treat GERD with proton‑pump inhibitors or lifestyle changes.
• Manage post‑nasal drip with intranasal corticosteroids or antihistamines.
• Optimize asthma or COPD therapy if underlying airway disease exists.

4. Follow‑up

Re‑evaluate blood‑pressure control 1–2 weeks after the medication change and monitor cough resolution. If cough persists >6 weeks despite medication adjustment, further pulmonology referral is appropriate.

Prevention Tips

• Start with the lowest effective quinapril dose. Lower doses reduce bradykinin accumulation.
• Ask about a history of ACE‑inhibitor cough. Patients who previously reacted to enalapril, lisinopril, or captopril are at higher risk.
• Consider an ARB as first‑line therapy for patients with known risk factors (e.g., asthma, chronic cough, smoking).
• Maintain hydration. Adequate fluid intake keeps airway secretions thin.
• Avoid smoking and second‑hand smoke. Tobacco irritates the airway and may amplify the cough.
• Monitor symptoms early. Keep a symptom diary for the first month after starting quinapril and report any new cough to your clinician promptly.

Emergency Warning Signs

Key Take‑aways

Quinapril‑induced cough is a common, usually benign side‑effect of ACE inhibitors caused by bradykinin buildup. Recognizing the pattern—dry, persistent cough that begins weeks after starting or increasing quinapril—allows clinicians to differentiate it from infection, asthma, or heart failure. The primary treatment is discontinuation or substitution with an ARB, and most patients experience symptom resolution within a month. Patients should stay vigilant for red‑flag symptoms that require urgent care and communicate any persistent cough to their healthcare provider.

---

References: Mayo Clinic. “ACE inhibitor cough.”; CDC. “Hypertension Management.”; NIH National Heart, Lung, and Blood Institute. “ACE Inhibitors and Side Effects.”; Cleveland Clinic. “Bradykinin and Cough.”; World Health Organization. “Guidelines for the Pharmacological Treatment of Hypertension.”

```